The long-term objective of the current human trials is to finalize the method (laser-assisted Immunotherapy) for the treatment of solid, metastatic tumors. Our immediate goal is to determine the optimal dosage for the alteration of the course of the disease, and reduce the tumor burden. At the same time, we assess objective responses based on physical and radiographic examination, hematology and blood chemistry.

Each patient is individually evaluated for toxicity tolerance through physical exams and by appropriate supplemental and routine laboratory tests (CSC, UA and complete metabolic profile) before and during therapy. Observable tumors in patients are followed with physical examination and radiological evaluations. Treatment efficacy is judged by the size and number of local and systemic metastases before and after treatment when patients are restaged with CT examinations. Secondary efficacy parameters include the values of the hematology and blood chemistry studies. Other immunological parameters are monitored that may reveal clues to the ultimate mechanism of action of this form of treatment.